



Universiteit  
Leiden  
The Netherlands

**Improving diagnosis and treatment of gastrointestinal stromal tumor (GIST) patients: Results from the Dutch GIST Registry**  
Farag-Kal, S.

**Citation**

Farag-Kal, S. (2020, September 16). *Improving diagnosis and treatment of gastrointestinal stromal tumor (GIST) patients: Results from the Dutch GIST Registry*. Retrieved from <https://hdl.handle.net/1887/136757>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/136757>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/136757> holds various files of this Leiden University dissertation.

**Author:** Farag-Kal, S.

**Title:** Improving diagnosis and treatment of gastrointestinal stromal tumor (GIST) patients: Results from the Dutch GIST Registry

**Issue Date:** 2020-09-16

# Paragraph 2.2

---

## Clinical characteristics and treatment outcome in a large multicenter observational cohort of *PDGFRA* exon 18 mutated gastrointestinal stromal tumor patients

---

Sheima Farag, Neeta Somaiah\*, Haesun Choi, Birthe Heeres, Wei-Lien Wang, Hester van Boven, Petra Nederlof, Robert Benjamin, Winette van der Graaf, Dirk Grunhagen, Pieter A. Boonstra, Anna K.L. Reyners, Hans Gelderblom, Neeltje Steeghs

\*Author contributed equally to the manuscript

*European Journal of Cancer* 2017; 76: 76-82

## **Purpose**

Platelet-derived growth factor receptor alpha (*PDGFRA*) D842V-mutated gastrointestinal stromal tumors (GISTs) are known for their insensitivity to imatinib. However, in clinical practice responses have been observed in some patients. We describe the natural history and treatment outcomes in a cohort of *PDGFRA* exon 18 mutated GIST patients.

## **Patients and methods**

A retrospective cohort study was conducted in *PDGFRA* exon 18 mutation GIST patients treated in six expert centers in the Netherlands and the United States. Two independent radiologists assessed radiological response to imatinib according to Choi's criteria in all patients with measurable disease treated with imatinib in neoadjuvant or palliative intent.

## **Results**

Seventy-one patients with *PDGFRA* exon 18 mutation were identified of whom 48 patients (69%) had a D842V mutation. Twenty-two (45.8%) D842V-mutated GIST patients received imatinib treatment, 16 had measurable disease. Fourteen out of the 23 (60.9%) patients with non-D842V mutations received imatinib treatment, eight had measurable disease. Two out of 16 (12.5%) D842V-mutated GIST patients had partial response, 3 patients (18.8%) had stable disease, and 9 patients (56.3%) had progressive disease as best response. Two patients did not have follow-up computed tomography scans to assess response. Six out of 8 (75%) patients with non-D842V exon 18 mutations had partial response and two (25%) had stable disease as best response.

## **Conclusion**

Patients with D842V-mutated GISTs can occasionally respond to imatinib. In the absence of better therapeutic options, imatinib should therefore not be universally withheld in patients with this mutation.

## Introduction

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Important to their tumorigenesis is an activating mutation involving a gene, which encodes for a tyrosine kinase receptor (TKR). Most commonly, this TKR is *KIT* (w75%) and in 10% of patients, platelet-derived growth factor receptor alpha (*PDGFRA*). Approximately 15% of all GISTs are wild type for *PDGFRA* and *KIT*.(1)

Systemic treatment with imatinib, an oral tyrosine kinase inhibitor (TKI), has been proven effective for a majority of patients with advanced GIST, showing response in up to 85% of advanced GIST patients.(2) In addition, patients with an operable GIST with a high risk of recurrence can improve their progression-free survival (PFS) with adjuvant imatinib. For these patients, adjuvant treatment with imatinib for 36 months increased PFS from 36% to 65.6%.(3,4) However, the affinity of TKIs depends on the type of mutation. The most common *PDGFRA* mutation, a D842V substitution in exon 18, shows primary resistance to imatinib in in vitro and in vivo studies.(5-7) Although D842V-mutated GISTs comprise a large majority of *PDGFRA* exon 18 GISTs, other mutations in exon 18 differ in their sensitivity to imatinib. It is therefore important to distinguish between resistant and sensitive mutations. However, few non-D842V GISTs have been described.(5,6,8)

According to the international guidelines, adjuvant treatment is not recommended for patients with D842V-mutated GIST.(9) However, there are no specific recommendations on treatment of these GIST patients with advanced disease.(9,10) Despite expected resistance to imatinib, some advanced D842V-mutated GIST patients end up receiving imatinib either because of an unknown mutation status at the time of treatment or due to the absence of better therapeutic options. In our daily practice we noted some D842V-mutated GIST patients who appeared to respond to imatinib treatment. Based on these anecdotal findings we conducted an observational study including data from six expert centers in the Netherlands and the United States. We describe treatment and responses in all GISTs harboring a mutation in *PDGFRA* exon 18.

## Methods

### Patient population

Three cohorts of patients were defined: (1) patients included in the Dutch GIST Registry (DGR); (2) patients with a *PDGFRA* exon 18 mutation identified from the pathology database of the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AvL) in Amsterdam, Netherlands and (3) patients with a *PDGFRA* exon 18 mutation identified from the pathology database of the MD Anderson Cancer Center (MDACC), Houston, USA.

The DGR includes all GIST patients diagnosed with GIST between January 2009 and March 2015 in the 5 GIST centers in the Netherlands: the NKI-AvL, Leiden University

Medical Center, Erasmus University Medical Center, Radboud University Nijmegen Medical Center and the University Medical Center Groningen.

Within the pathology database of the NKI-AvL all GIST patients diagnosed before January 2009 with *PDGFRA* exon 18 mutations were identified. Patients identified from the pathology databases were included in the analyses when a medical record was available. Data acquisition was approved by the local independent ethics committees, and the study was conducted in accordance with the Declaration of Helsinki.

### **Clinical data selection**

The DGR contains demographic and clinical variables, including age, sex, relevant family history and primary tumor location, size and stage. Furthermore, pathology reports describing histology, immunohistochemistry and mutational status are entered in the database. Local and systemic therapies and all hospital visits were registered, including computed tomography (CT) scans and magnetic resonance imaging. For patients who were not entered in the DGR, clinical data points were collected using medical records.

### **Molecular diagnosis**

For MDACC patients, polymerase chain reaction (PCR) based DNA sequencing for *KIT* and *PDGFRA* was performed at the Molecular Diagnostics Laboratory at the University of Texas MDACC. Formalin fixed paraffin-embedded blocks with tumor were selected and 4 mm-thick sections prepared. Genomic DNA samples were isolated from micro-dissected paraffin-embedded slides using a QIAamp DNA miniKIT (Qia-gen, Germantown, MD, USA). For PCR, primer sets for exons 9, 11, 13 and 17 of the *KIT* gene and for exon 18 of the *PDGFRA* gene were used. PCR was carried out in a total volume of 25 µl containing 50-100 ng of genomic DNA and 0.25 µl of DNA polymerase (Bioline, London, UK). Mutations were identified by sequencing the PCR products on a 3730 1 DNA analyzer (Applied Biosystems, Carlsbad, CA, USA).

For most Dutch sites, routine mutation analysis included analysis of *KIT* (exons 9, 11, 13 and 17) and *PDGFRA* (exons 12, 14 and 18) by Sanger Sequencing. Five to 10 mm formalin fixed paraffin embedded (FFPE) sections of tumor material were used for DNA isolation using standard procedures (KAPA Express Extract KIT, Kapa Biosystems, Massachusetts, USA). An area for micro-dissection of tumor cells was indicated by a pathologist. Sequencing was performed on a capillary sequencer (ABI 3730 DNA Analyzer, Life Technologies, USA), mutation analysis was performed using specific software (Mutation Surveyor, Softgenetics, USA).

For validation purposes, repeated molecular analyses were performed in samples from multiple sites of the resected tumors for all patients with a D842V-mutated GIST with partial response (PR).

### **Radiological response evaluation**

In all patients with measurable disease treated in neo-adjuvant or palliative setting radiological tumor measurements were re-evaluated by two independent radiologists using Choi's criteria: PR was defined as at least 10% decrease in maximal diameter as measured according to Response Evaluation Criteria in Solid Tumors (RECIST) or 15% decrease or more in Hounsfield units; progressive disease (PD) was determined in case of an increase in tumor diameter of 10% and if the tumor does not meet the PR criteria by tumor attenuation on CT; if the tumor did not meet either of the criteria for PR or PD, response was defined as stable disease (SD).<sup>(11)</sup> If the outcomes of both radiologists did not correspond, an outcome was determined based on consensus.

### **Pathological response evaluation**

Histologic response evaluation was conducted in patients who received imatinib prior to surgery. Response was graded based on the microscopic amount of necrosis and fibrosis according to the following scheme that is based on consensus between pathologists in the MD Anderson and the NKI-AvL: (1) minimal, <10%; (2) moderate, 10-50% and (3) good, >50%. Grading was done at the MDACC and in the AvL-NKI population separately.

### **Statistical analysis**

Median time to progression (TTP) was calculated for all patients with measurable disease treated with neo-adjuvant or palliative intent. It was calculated from the date of initiation of imatinib treatment to the date of radiological or clinical progression prompting the physician to change treatment strategy. Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) version 22.0.

## **Results**

### **Patient numbers**

In the DGR, 678 GIST patients were identified of whom 42 patients with GIST harboring a mutation in *PDGFRA* exon 18. The pathology databases of the NKI-AvL and the MDACC revealed 29 additional *PDGFRA* exon 18 mutated GIST patients; 10 at the NKI-AvL and 19 at the MDACC. In total, 71 non-overlapping GIST patients were identified with a *PDGFRA* exon 18 mutation of whom 48 (69%) patients with a D842V-mutated GIST (Figure 1).

### **D842V-mutated GISTs**

Over 90% of patients had local or locally advanced disease at registry entry. Twenty-two patients received systemic treatment with imatinib out of which 17 patients were treated with neo-adjuvant or palliative intent. All but one had measurable disease at the start of therapy, since this lesion was below the detection criteria for CT evaluation (Table 1). Two patients had PR (Figure 2). Three patients had SD, and 9 patients had PD as best response.

For 2 patients, no follow-up CT scans were available; one patient underwent resection shortly after the start of therapy and one patient had started therapy recently and was therefore not evaluable yet. Pathological response was evaluated in 7 out of 12 neo-adjuvant treated patients. None of these cases showed a good pathologic response (Table 2). Repeated molecular analyses in different parts of the tumor from the two patients showing PR confirmed a D842V mutation in all tumor regions.

Median follow-up time for all patients receiving imatinib with neo-adjuvant and palliative intent was 11 months (range 0-131). Out of 17 patients treated with neo-adjuvant and palliative intent, 10 patients showed PD. Median TTP was 8 months (range 0-42). Patients who progressed on imatinib showed a median TTP of 2.5 months (range 0-8). Five patients had died during follow-up, 3 due to disease progression.

Three out of 11 patients in the high-risk category received adjuvant treatment, and no patients showed recurrence in this group during median follow-up period of 23 months (range 1-84). Out of 8 high-risk patients who did not receive adjuvant treatment two had recurrence during the follow-up period.

### **Non-D842V mutated GISTs**

Seventeen patients with a non-D842V mutated GIST had local or locally advanced disease at registry entry. Three patients received imatinib with neo-adjuvant intent and 5 with palliative intent, resulting in 8 non-D842V mutated GIST patients with measurable disease. Six patients had PR and two patients had SD as best response. Good pathologic response was seen in one patient harboring an I843\_D846del mutation out of 2 patients who had pathologic evaluation. Table 2 describes all specific mutations in *PDGFRA* exon 18 in patients with measurable disease and their responses (Table 2).

Median follow-up time for patients receiving imatinib with neo-adjuvant or palliative intent was 24.5 months (range 3-132). Two patients had progression; one patient progressed within 7 months and the other patient progressed within 27 months.

Three out of the four high-risk patients received adjuvant treatment. One had recurrence after 1 year of adjuvant imatinib therapy. Two patients, who did not receive adjuvant treatment, also had recurrence. One of them had high-risk disease, the other had an unknown risk category.




**Table 1:** Patient characteristics.

Characteristics	Total (71)	D842V-mutated GISTs N = 48	Non-D842V mutated GISTs N = 23
Sex (male)	43 (60.6%)	28 (58.3%)	15 (65.2%)
Age in years (median; range)	58 (23-87)	56 (23-80)	62 (46-87)
Tumor status at registry			
Localized disease	48 (67.6%)	33 (68.8%)	15 (65.2%)
Locally advanced	13 (18.3%)	11 (22.9%)	2 (8.7%)
Metastasized	10 (14.1%)	4 (8.3%)	6 (26.1%)
Primary tumor location			
Gastric	65 (91.5%)	44 (91.7%)	21 (91.3%)
Oesophagus	1 (1.4%)	-	1 (4.3%)
Unknown/miscellaneous	5 (7.1%)	4 (8.3%)	1 (4.3%)
Primary tumor size in mm (median; range)	85 (7-310)	90 (12-310)	62 (7-260)
Histology			
Spindle cell	32 (45.1%)	26 (54.2%)	6 (26.1%)
Epithelioid	24 (33.8%)	12 (25.0%)	12 (52.2%)
Mixed	11 (15.5%)	7 (14.6%)	4 (17.4%)
Not reported	4 (5.6%)	3 (6.3%)	1 (4.3%)
Mitotic index (per 5mm <sup>2</sup> )			
5	41 (57.7%)	31 (64.6%)	10 (43.5%)
>5	16 (22.5%)	10 (20.8%)	6 (26.1%)
Unknown	14 (19.7%)	7 (14.6%)	7 (30.4%)
Risk category <sup>a</sup>			
Low risk	35 (53.5%)	26 (60.4%)	9 (39.1%)
High risk	15 (14.1%)	11 (12.5%)	4 (17.4%)
Insufficient information	11 (18.3%)	7 (18.8%)	4 (17.4%)
NA <sup>b</sup>	10 (14.1%)	4 (8.3%)	6 (26.1%)
Surgery			
Yes	64 (90.1%)	43 (89.6%)	21 (91.3%)
No	7 (9.9%)	5 (10.4%)	2 (8.7%)
Imatinib treatment			
Yes	36 (47.9%)	22 (45.8%)	14(60.9%)
No	35(52.1%)	26(54.2%)	9(39.1%)
Treatment objective			
Neo-adjuvant	15 (18.3%)	12 (20.8%)	3 (13.0%)
Palliative	10 (14.1%)	5 (12.5%)	5 (17.4%)
Adjuvant	11 (18.3%)	5 (12.5%)	6 (30.4%)
No treatment	35 (49.3%)	25 (54.2%)	9 (39.1%)

GISTs: gastrointestinal stromal tumors

<sup>a</sup> Risk category according to Miettinen's criteria.

<sup>b</sup> Patients presented with metastatic disease, therefore no risk category is applicable.



**Figure 1:** Flowchart describing inclusion of GIST patients with *PDGFRA* exon 18 mutations.



**Figure 2:** (A) Radiological response in a neo-adjuvant treated D842V-mutated GIST patient. (B) Radiological response in a D842V-mutated GIST patient treated with palliative intent.

**Table 2:** Radiological Choi responses and pathological responses in patients with measurable disease treated with palliative or neo-adjuvant intent.

PDGFRA exon 18 mutation type	Radiological responses				Pathological responses				Total*
	Partial response	Stable disease	Progressive disease	No data	Good	Intermediate	None	No data	
D842V	2 (12.5%)	3 (18.8%)	9 (56.3%)	2 (12.5%)	0 (0.0%)	1 (6.3%)	6 (37.5%)	9 (56.3%)	16
Other exon 18 mutations	6 (75.0%)	2 (25.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	0 (0.0%)	1 (12.5%)	6 (75.0%)	8
p.D842_D846delinsG	0	1	0	0	0	0	0	0	1
p.D842_H845del	1	0	0	0	0	0	0	0	1
p.D842_N848del	1	0	0	0	0	0	1	0	0
p.D842Y	1	0	0	0	0	0	0	0	1
p.I843_D846del	1	0	0	0	1	0	0	0	0
p.I843_S847delinsT	0	1	0	0	0	0	0	0	1
p.Y849H	1	0	0	0	0	0	0	0	1
Other mutations in exon 18 not further specified	1	0	0	0	0	0	0	0	1

\* Could only be assessed in patients treated with imatinib prior to surgery.

## Discussion

We assessed responses to imatinib in GIST patients harboring a *PDGFRA* exon 18 mutation in a large observational cohort treated in routine clinical care. Interestingly, we showed that a small fraction of D842V-mutated GISTs respond to treatment with imatinib. One remains recurrence-free after neo-adjuvant treatment for almost 3 years and the other is progression-free during the 10 years of follow-up.

The response to imatinib in D842V-mutated GIST in our study contrasts the responses described in prior in vivo and in vitro studies. In these studies, D842V mutation has consistently shown to be imatinib-resistant.(5,6) In one study by Cassier et al. (2012), in vivo response was described in 32 D842V-mutated GISTs, showing no PR, 21 patients with PD and the rest with SD as the best response.(6) These findings are similar to those found in the study conducted by Corless et al., in 2005.(5) They found 35 patients in their study and 181 unique patients in total described in literature with a D842V mutation in exon 18. None of these patients showed response to imatinib. In these studies, response evaluations were conducted by RECIST. It is well known that response by Choi's criteria is correlated with TTP and that size-based response criteria may lead to an underestimation of the imatinib response in GIST.(12,13) However, the responses in the two D842V-mutated GIST patients in our study would have been classified as PR even by RECIST guidelines. Though no additional mutations were detected in our patient samples and repeated molecular analyses confirmed D842V mutation, one could speculate that heterogeneity within the tumor might have resulted in the responses noted in our patients.(14)

Similar to the earlier studies a large proportion of the D842V-mutated patients had PD as best response with a short TTP. This resistance to imatinib is thought to be the result of D842V mutation affecting the tyrosine kinase receptor activation loop. A D842V mutation in *PDGFRA* leads to reduced accessibility of the adenosine triphosphate (ATP) pocket and thereby to relative resistance to imatinib.(1) Corless et al. have found that other substitutions in codon 842, except for D842Y, also show resistance to imatinib.(5)

In line with prior studies we found that patients with a non-D842V mutated GIST respond well to imatinib. Despite the fact that the imatinib-resistant D842V mutation comprises a large majority of mutations in *PDGFRA* exon 18, approximately 30% have other mutations involving exon 18 of *PDGFRA* and all have shown favourable responses to imatinib.(5,15,16) Also, median TTP in our non-D842V mutated GIST patients with advanced disease was similar to other imatinib sensitive GIST patients.

International guidelines regarding adjuvant and neo-adjuvant treatment do not recommend imatinib for GIST patients harboring a D842V mutation.(9) It is therefore important to perform mutation analysis to determine the driver mutation and its sensitivity to imatinib. Interestingly, imatinib with neo-adjuvant and adjuvant intent was still frequently given in our cohort of D842-mutated GIST. It is possible that the mutation results were not available at the time of initiation of therapy. Nine D842V-mutated GIST

patients in our cohort were given adjuvant or neo-adjuvant treatment. Patients with *PDGFRA* exon 18 mutated GIST often have low mitotic activity and are considered to be low risk. Joensuu et al. showed that a mitotic count of over 5 per 50 high power field predicts for high risk for recurrence.(15) It is unknown whether with D842V-mutated GIST might benefit from adjuvant treatment. Although in our cohort slightly more recurrences occurred in non-treated patients with a high-risk tumor, no conclusions can be drawn considering the low patient numbers and heterogeneous follow-up time.

In case of a locally advanced tumor, the European Society for Medical Oncology (ESMO) guideline recommends resection without prior imatinib therapy in less sensitive tumors like D842V-mutated GISTs. Twelve of our patients with locally advanced GIST received imatinib and a quarter did not undergo surgery eventually. Again, it is unclear if the treating physician had the mutation data available at the time of treatment initiation.

For GIST patients harboring a D842V mutation with advanced disease no specific recommendations on treatment are described in international guidelines.(9,10) Given the known resistance to imatinib in D842V-mutated GIST, therapeutic alternatives are being investigated but proven therapies are still lacking.(17-20) Therefore, it was not a surprise to us that imatinib is still given in routine clinical care and this helped us evaluate the utility of imatinib in this population.

Patients in our study were treated in six different expert centers, resulting in a representative sample of patients. Evaluation of best response was confirmed by two independent radiologists according to Choi's criteria. No prior study has described in vivo pathologic response in *PDGFRA* exon 18 patients. Agaram et al. showed little to no correlation between radiological and pathological response in GIST patients.(21) There is however evidence that patients with good pathological response show better PFS and overall survival (OS).(22) In our cohort, only one patient with good radiological response to imatinib had good pathologic response. Further interpretation is limited due to small numbers.

Even though our sample size is small, considering the rarity of *PDGFRA* exon 18 mutated GISTs, this is the first and largest cohort to date of patients treated in routine clinical care described in the literature. Unlike what has previously been described we have found clinical and radiological responses in few patients with D842V-mutated GIST. Considering that GIST might be a multiclonal disease, one might argue that these patients could have had different clones within their tumors. Therefore, in our view imatinib treatment should not be universally denied in D842V-mutated GISTs who are not surgically resectable. Given the lack of alternative treatments in advanced disease, it may be worth while to start imatinib treatment in D842V-mutated GISTs with frequent response evaluations.

## **Disclosures**

Dr. Neeltje Steeghs received a research grant from Novartis, Bayer and Pfizer for the Dutch GIST Registry. Prof. Winette van der Graaf received a preclinical research grant from Novartis.

## **Funding**

A research grant for the Dutch GIST Registry was received from Novartis, Bayer and Pfizer.

## **Conflict of interest statement**

None declared.

## References

1. Corless CL. Gastrointestinal stromal tumors: what do we know now? *Mod Pathol* 2014;27(Suppl. 1):S1-16.
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumor. *Lancet* 2013;382(9896):973-83.
3. Joensuu H, Eriksson M, Sundby Hall K, Hartman JT, Pink D, Schutte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. *Jama* 2012;307(12):1265-72.
4. Joensuu H, Vehtari A, Riihimaäki J, Nishida T, Steigen SE, Brabec P, et al. Risk of recurrence of gastrointestinal stromal tumor after surgery: an analysis of pooled population-based cohorts. *Lancet Oncol* Mar. 2012;13(3):265-74.
5. Corless CL. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. *J Clin Oncol* 2005;23(23):5357-64.
6. Cassier PA, Fumagalli E, Rutkowski P, Schoffski P, Van GM, biećRychter M, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. *Clin Cancer Res* 2012; 18(1078-0432):4458-64.
7. Wang W-L, Conley A, Reynoso D, Nolden L, Lazar AJ, George S, et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. *Cancer Chemother Pharmacol* 2011;67(Suppl. 1):S15-24.
8. Kunstlinger H, Binot E, Merkelbach-Bruse S, Huss S, Wardelmann E, Buettner R, et al. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive *PDGFRA* exon 18 mutations in gastrointestinal stromal tumors. *Hum Pathol* 2014;45(3):573-82.
9. The ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* Sep. 2014;25(3):iii21-6.
10. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. *J Natl Compr Canc Netw* 2010;8(Suppl. 2):S1-41. quiz S42-S44.
11. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. *AJR Am J Roentgenol* Dec. 2004;183(6):1619-28.
12. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST, at least in GIST. *J Clin Oncol* May 2007;25(13):1760-4.
13. Choi H. Response evaluation of gastrointestinal stromal tumors. *Oncologist* 2008;13(Suppl. 2):4-7.

14. Gao J, Li J, Li Y, Li Z, Gong J, Wu J, et al. Intratumoral *KIT* mutational heterogeneity and recurrent *KIT/PDGFR*A mutations in *KIT/PDGFR*A wild-type gastrointestinal stromal tumors. *Oncotarget* Feb. 2016;7(21):30242-9.
15. Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, et al. *KIT* and *PDGFR*A mutations and the risk of GI stromal tumor recurrence. *J Clin Oncol* 2015;33(6):634-42.
16. Fanta PT. In vivo imatinib sensitivity in a patient, vol. 33 (8); 2015. p. 41-4.
17. Heinrich MC, Griffith D, McKinley A, Patterson J, Presnell A, Ramachandran A, et al. Crenolanib inhibits the drug-resistant *PDGFR*A D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. *Clin Cancer Res* 2012;18: 4375-84.
18. Weisberg E, Wright RD, Jiang J, Ray A, Moreno D, Manley PW, et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated *PDGFR*A mutants with differential imatinib sensitivity. *Gastroenterology* 2006;131(6):1734-42.
19. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. *Gastroenterology* Feb. 2005;128(2):270-9.
20. Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated *PDGFR*A D842V mutation. *Clin Cancer Res* Sep. 2008;14(18):5749-58.
21. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, et al. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. *Clin Cancer Res* 2007;13(1):170-81.
22. Cheng C-T, Tsai C-Y, Yeh C-N, Chiang K-C, Chen Y-Y, Wang S-Y, et al. Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment lessons learned. *Anti-cancer Res* Nov. 2014;34(11):6617-25.





